Etrolizumab vs placebo
Failure to induce clinical remission at end of study · patients with induction of remission in ulcerative colitis
Etrolizumab probably leads to lower failure to enter clinical remission at week 10 ‐ 100 mg compared with placebo (moderate certainty).
1 finding from 1 review
- RR 0.81 [0.68, 0.96]1 study · 59 participantsModerate